B & T Capital Management Dba Alpha Capital Management Biomarin Pharmaceutical Inc Transaction History

B & T Capital Management Dba Alpha Capital Management

$485 Million
Q2 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 01, 2021	SELL	$74.77 - $85.47 $1.44 Million - $1.64 Million	-19,238 Closed	0 $0
Q2 2021 Jul 23, 2021	BUY	$75.51 - $84.79 $73,848 - $82,924	978 Added 5.36%	19,238 $1.61 Million
Q1 2021 May 03, 2021	BUY	$74.73 - $90.69 $43,418 - $52,690	581 Added 3.29%	18,260 $1.38 Million
Q4 2020 Feb 02, 2021	BUY	$72.61 - $90.2 $29,987 - $37,252	413 Added 2.39%	17,679 $1.55 Million
Q3 2020 Nov 12, 2020	SELL	$71.87 - $131.03 $51,818 - $94,472	-721 Reduced 4.01%	17,266 $1.31 Million
Q2 2020 Jul 29, 2020	SELL	$79.55 - $124.22 $36,513 - $57,016	-459 Reduced 2.49%	17,987 $2.22 Million
Q1 2020 May 05, 2020	BUY	$71.37 - $96.85 $46,390 - $62,952	650 Added 3.65%	18,446 $1.56 Million
Q4 2019 Jan 17, 2020	SELL	$64.27 - $86.37 $40,104 - $53,894	-624 Reduced 3.39%	17,796 $1.51 Million
Q3 2019 Oct 29, 2019	BUY	$67.4 - $85.11 $69,826 - $88,173	1,036 Added 5.96%	18,420 $1.24 Million
Q2 2019 Aug 01, 2019	BUY	$80.35 - $93.9 $1.4 Million - $1.63 Million	17,384 New	17,384 $1.49 Million

Others Institutions Holding BMRN

# of Institutions

632

Shares Held

185M

Call Options Held

1.63M

Put Options Held

1.2M

Black Rock Inc. New York, NY

22.7M
Shares

$1.6 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19M
Shares

$1.34 Billion
0.03% of portfolio
Primecap Management CO Pasadena, CA

18.8M
Shares

$1.33 Billion
1.14% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$983 Million
0.72% of portfolio
Capital Research Global Investors Los Angeles, CA

9.69M
Shares

$684 Million
0.18% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of B & T Capital Management Dba Alpha Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on B & T Capital Management Dba Alpha Capital Management with notifications on news.

Account